Fig. 4From: Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trialSimulated concentration–time curves for patients with various weights following sapropterin (10 mg/kg/day)Back to article page